相关实验视频
Updated: Sep 11, 2025

Osteoclast Derivation from Mouse Bone Marrow
Published on: November 6, 2014
骨质细胞前体细胞衍生Flot2是一种新的治疗点,用于骨质损失疾病
Binhua Zou1, Jiehuang Zheng2, Weili He3
1Laboratory of Anti-inflammatory and Immunomodulatory Pharmacology, Innovation Program of Drug Research on Inflammatory and Immune Diseases, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China; Department of Rehabilitation Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
使用siRNA的Flot2抑制降低了骨质疏松症和乳腺癌等骨质损失疾病的病态骨质细胞形成. 血液细胞中的FLOT2蛋白可能有助于早期发现乳腺癌.
科学领域:
- 生物医学研究的研究.
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 过度的骨质细胞生成会导致骨质疏松症和乳腺癌等疾病的骨质损失.
- 目前的骨质结晶抑制剂具有严重的副作用,并影响骨形成.
- 小干扰RNA (siRNA) 药物是新兴的治疗方法.
研究的目的:
- 为了研究flotillin-2 (Flot2) 在骨质细胞形成中的作用.
- 评估Flot2-siRNA作为骨解病的潜在治疗方法.
- 探索FLOT2作为乳腺癌的诊断标志物.
主要方法:
- 用CRISPR/Cas9和siRNA在体外和体内消去Flot2.
- 使用了卵巢切除术诱导的骨质疏松症和乳腺癌细胞诱导的骨质溶解模型.
- 分析了周围血液中CD14+细胞中的FLOT2蛋白水平.
主要成果:
- 在骨质疏松症模型中,Flot2切除抑制了骨质结晶生成并减少了骨质损失,而不会影响正常的骨质量.
- 弗洛特2缺乏破坏了弗洛特2-PLCγ2相互作用,减少了骨质细胞形成.
- Flot2-siRNA-AAV阻断了乳腺癌诱导的骨质溶解.
- 针对FLOT2的siRNA抑制了患者衍生细胞中的骨质结晶发生.
- 血液细胞中异常的FLOT2蛋白水平区分了恶性乳腺癌和良性瘤.
结论:
- Flot2-siRNA是一种潜在的治疗药物,用于骨解病的病态骨质细胞形成.
- 外围骨质细胞前体细胞中的FLOT2蛋白可以作为早期乳腺癌诊断的新生物标志物.
相关概念视频
Osteoclasts in Bone Remodeling
Bone Remodeling
Bone Cells and Tissue
Osteoblasts and Osteocytes
The osteoblast is the bone cell responsible for forming new bone tissue. It is found in the growing portions of bone, including the...
Bone Formation by Endochondral Ossification
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...

